BIOMAT Database Logo BIOMAT Database Logo

Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation. 2020

Peng Chen, and Xiaojun Luo, and Guanqi Dai, and Yuchuan Jiang, and Yue Luo, and Shuang Peng, and Hao Wang, and Penghui Xie, and Chen Qu, and Wenyu Lin, and Jian Hong, and Xue Ning, and Aimin Li
Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315, Guangzhou, China.

Dexmedetomidine (DEX) is an anesthetic that is widely used in the clinic, and it has been reported to exhibit paradoxical effects in the progression of multiple solid tumors. In this study, we sought to explore the mechanism by which DEX regulates hepatocellular carcinoma (HCC) progression underlying liver fibrosis. We determined the effects of DEX on tumor progression in an orthotopic HCC mouse model of fibrotic liver. A coculture system and a subcutaneous xenograft model involving coimplantation of mouse hepatoma cells (H22) and primary activated hepatic stellate cells (aHSCs) were used to study the effects of DEX on HCC progression. We found that in the preclinical mouse model of liver fibrosis, DEX treatment significantly shortened median survival time and promoted tumor growth, intrahepatic metastasis and pulmonary metastasis. The DEX receptor (ADRA2A) was mainly expressed in aHSCs but was barely detected in HCC cells. DEX dramatically reinforced HCC malignant behaviors in the presence of aHSCs in both the coculture system and the coimplantation mouse model, but DEX alone exerted no significant effects on the malignancy of HCC. Mechanistically, DEX induced IL-6 secretion from aHSCs and promoted HCC progression via STAT3 activation. Our findings provide evidence that the clinical application of DEX may cause undesirable side effects in HCC patients with liver fibrosis.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon

Related Publications

Peng Chen, and Xiaojun Luo, and Guanqi Dai, and Yuchuan Jiang, and Yue Luo, and Shuang Peng, and Hao Wang, and Penghui Xie, and Chen Qu, and Wenyu Lin, and Jian Hong, and Xue Ning, and Aimin Li
Stimulated hepatic stellate cell promotes progression of hepatocellular carcinoma due to protein kinase R activation.
January 2019, PloS one,
Peng Chen, and Xiaojun Luo, and Guanqi Dai, and Yuchuan Jiang, and Yue Luo, and Shuang Peng, and Hao Wang, and Penghui Xie, and Chen Qu, and Wenyu Lin, and Jian Hong, and Xue Ning, and Aimin Li
HK1 from hepatic stellate cell-derived extracellular vesicles promotes progression of hepatocellular carcinoma.
October 2022, Nature metabolism,
Peng Chen, and Xiaojun Luo, and Guanqi Dai, and Yuchuan Jiang, and Yue Luo, and Shuang Peng, and Hao Wang, and Penghui Xie, and Chen Qu, and Wenyu Lin, and Jian Hong, and Xue Ning, and Aimin Li
PRDM16 from hepatic stellate cells-derived extracellular vesicles promotes hepatocellular carcinoma progression.
January 2023, American journal of cancer research,
Peng Chen, and Xiaojun Luo, and Guanqi Dai, and Yuchuan Jiang, and Yue Luo, and Shuang Peng, and Hao Wang, and Penghui Xie, and Chen Qu, and Wenyu Lin, and Jian Hong, and Xue Ning, and Aimin Li
Hepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialin.
June 2017, EMBO molecular medicine,
Peng Chen, and Xiaojun Luo, and Guanqi Dai, and Yuchuan Jiang, and Yue Luo, and Shuang Peng, and Hao Wang, and Penghui Xie, and Chen Qu, and Wenyu Lin, and Jian Hong, and Xue Ning, and Aimin Li
MIRLET7BHG promotes hepatocellular carcinoma progression by activating hepatic stellate cells through exosomal SMO to trigger Hedgehog pathway.
March 2021, Cell death & disease,
Peng Chen, and Xiaojun Luo, and Guanqi Dai, and Yuchuan Jiang, and Yue Luo, and Shuang Peng, and Hao Wang, and Penghui Xie, and Chen Qu, and Wenyu Lin, and Jian Hong, and Xue Ning, and Aimin Li
Hepatic Stellate Cell Modulates the Immune Microenvironment in the Progression of Hepatocellular Carcinoma.
September 2022, International journal of molecular sciences,
Peng Chen, and Xiaojun Luo, and Guanqi Dai, and Yuchuan Jiang, and Yue Luo, and Shuang Peng, and Hao Wang, and Penghui Xie, and Chen Qu, and Wenyu Lin, and Jian Hong, and Xue Ning, and Aimin Li
GJA1 promotes hepatocellular carcinoma progression by mediating TGF-β-induced activation and the epithelial-mesenchymal transition of hepatic stellate cells.
January 2021, Open medicine (Warsaw, Poland),
Peng Chen, and Xiaojun Luo, and Guanqi Dai, and Yuchuan Jiang, and Yue Luo, and Shuang Peng, and Hao Wang, and Penghui Xie, and Chen Qu, and Wenyu Lin, and Jian Hong, and Xue Ning, and Aimin Li
RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A.
September 2020, Scientific reports,
Peng Chen, and Xiaojun Luo, and Guanqi Dai, and Yuchuan Jiang, and Yue Luo, and Shuang Peng, and Hao Wang, and Penghui Xie, and Chen Qu, and Wenyu Lin, and Jian Hong, and Xue Ning, and Aimin Li
CSNK2A2 promotes hepatocellular carcinoma progression through activation of NF-κB pathway.
January 2023, Annals of hepatology,
Peng Chen, and Xiaojun Luo, and Guanqi Dai, and Yuchuan Jiang, and Yue Luo, and Shuang Peng, and Hao Wang, and Penghui Xie, and Chen Qu, and Wenyu Lin, and Jian Hong, and Xue Ning, and Aimin Li
Treatment-damaged hepatocellular carcinoma promotes activities of hepatic stellate cells and fibrosis through GDF15.
September 2018, Experimental cell research,
Copied contents to your clipboard!